Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 7/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17923376 | 1.00 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL14990911 | 0.92 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL17923359 | 0.92 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL14991295 | 0.91 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL14856715 | 0.88 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1HSP90B1 | |
| SCHEMBL14856235 | 0.88 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL17923369 | 0.88 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL14856229 | 0.86 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL17923356 | 0.86 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1HSP90B1HDAC8 | |
| SCHEMBL14856002 | 0.85 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1HSP90B1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193200-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-07-07 | — | — | US | claimed |
| US-9321718-B2 | Benzamide derivatives and their use as HSP90 inhibtors | CHROMA THERAPEUTICS LTD. (GB) | 2016-04-26 | — | — | US | claimed |
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2013-06-06 | — | — | US | claimed |
| US-20160193200-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-07-07 | — | — | US | disclosed |
| US-9321718-B2 | Benzamide derivatives and their use as HSP90 inhibtors | CHROMA THERAPEUTICS LTD. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2013-06-06 | — | — | US | disclosed |
| EP-2580193-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | Chroma Therapeutics Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154708-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD (GB) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193200-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 4/4885 |
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885HSP90B1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.